Is It Time to Rethink the Expanded-Access Programs for HIV Infection?

Amorosa, Valerianna; Tebas, Pablo
October 2007
Journal of Infectious Diseases;10/1/2007, Vol. 196 Issue 7, p974
Academic Journal
The purpose of expanded-access programs (EAPs) for antiretroviral therapy has been to allow patients without alternative treatment options to obtain drugs before formal Food and Drug Administration approval. Given the dramatic changes that have occurred in antiretroviral therapeutic approaches during the past 2 decades, we wish to review the history of antiretroviral EAPs and to propose an updated model for expanded access that would achieve maximal patient benefit and add useful knowledge that could guide treatment decisions in patients infected with multidrug-resistant human immunodeficiency virus.


Related Articles

  • Physical Symptoms, Beliefs About Medications, Negative Mood, and Long-Term HIV Medication Adherence. Gonzalez, Jeffrey S.; Penedo, Frank J.; Llabre, Maria M.; Durán, Ron E.; Antoni, Michael H.; Schneiderman, Neil; Horne, Rob // Annals of Behavioral Medicine;2007, Vol. 34 Issue 1, p46 

    Background: Near-perfect levels of HIV medication adherence are necessary for treatment to be successful. However, many patients continue to report nonadherence to HIV treatment. Purpose: This study examines the relationship between symptoms of HIV and medication adherence and evaluates beliefs...

  • Pansinusitis in an HIV-infected patient due to Scedosporium apiospermum (Pseudallescheria boydii complex). Kenyon, C.; Mendelson, M.; Lubbe, D.; Khoury, B.; Vismer, H.; Hoffman, R. // Southern African Journal of Epidemiology & Infection;2011, Vol. 26 Issue 2, p88 

    Pseudallescheria boydii is a very rare cause of sinusitis but an increasingly recognised infection among HIV-infected patients. Its correct identification is vital as voriconazole, which has good in vitro activity against the fungus, has important interactions with antiretroviral drugs. We...

  • Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial. Dejesus, Edwin; McCarty, Debra; Farthing, Charles F.; Shortino, Denise D.; Grinsztejn, Beatriz; Thomas, Deborah A.; Schrader, Shannon R.; Castillo, Steve A.; Sension, Michael G.; Gough, Kevin; Madison, Sam J. // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p411 

    A randomized, double-blind, double-dummy controlled, multicenter trial was conducted that involved 554 antiretroviral-naive human immunodeficiency virus-infected adults (plasma HIV type 1 [HIV-1] RNA level, ⩾400 copies/mL; CD4+ cell count, >100 cells/mm³) and compared a 300-mg once-daily...

  • HIV-1 Superinfection in the Antiretroviral Therapy Era: Are Seroconcordant Sexual Partners at Risk? Campbell, Mary S.; Gottlieb, Geoffrey S.; Hawes, Stephen E.; Nickle, David C.; Wong, Kim G.; Deng, Wenjie; Lampinen, Thomas M.; Kiviat, Nancy B.; Mullins, James I. // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Acquisition of more than one strain of human immunodeficiency virus type 1 (HIV-1) has been reported to occur both during and after primary infection, but the risks and repercussions of dual and superinfection are incompletely understood. In this study, we evaluated a longitudinal...

  • Incorporating Drug-Resistance Measurements into the Clinical Management of HIV-1 Infection. Zolopa, Andrew R. // Journal of Infectious Diseases;9/16/2006, Vol. 194, pS59 

    Testing for resistance to antiretrovirals is considered to be standard of care and is widely used in the management of human immunodeficiency virus (HIV)-infected persons. Despite the widespread use of resistance testing, the clinician still faces a number of challenges when applying these...

  • A Brief Update on the AIDS Epidemic. Kopansky-Giles, Deborah // Journal of the American Chiropractic Association;Dec2004, Vol. 41 Issue 12, p40 

    Presents a brief update on the AIDS epidemic. Approximation made by the Joint United Nations Program on HIV/AIDS on the number of people who were infected with HIV by December 2003; Success of the Highly Active Antiretroviral Therapy in reducing viral load in people living with AIDS; Role played...

  • Why are some HIV/AIDS patients reluctant to receive antiviral therapy as soon as possible in China? Yang Sun; Hongzhou Lu // BioScience Trends;Jun2014, Vol. 8 Issue 3, p189 

    In more than 20 years of medical practice, a surprising phenomenon has often occurred: some patients with acquired immunodeficiency syndrome (AIDS) decide not to go to the hospital and they do not let others know that they are suffering from the disease unless they believe that they are dieing....

  • Candidiasis and HIV-Protease Inhibitors: The Expected and the Unexpected. Tacconelli, Evelina; Savarino, Andrea; de Bernardis, Flavia; Cauda, Roberto; Cassone, Antonio // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2004, Vol. 4 Issue 1, p49 

    What is largely known is that HIV-protease inhibitors (HIV-PI) have substantially contributed to the reduction of morbidity and mortality presently enjoyed by AIDS patients under highly active antiretroviral therapy (HAART). What is much less known is that they share rather remarkable inhibitory...

  • Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. Barbaro, Giuseppe; Scozzafava, Andrea; Mastrolorenzo, Antonio; Supuran, Claudiu T. // Current Pharmaceutical Design;May2005, Vol. 11 Issue 14, p1805 

    Highly active antiretroviral therapy (HAART) dramatically changed the course of HIV infection. Currently, this therapy involves the use of agents from at least two distinct classes of antivirals: a protease inhibitor (PI) in combination with two nucleoside/nucleotide reverse transcriptase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics